Oklahoma reaches $250 million opioid settlement with drug distributors
Reuters
Published Jun 27, 2022 05:08PM ET
Updated Jun 27, 2022 08:30PM ET
(Reuters) -Oklahoma has reached a $250 million settlement with AmerisourceBergen (NYSE:ABC) Corp, Cardinal Health Inc (NYSE:CAH) and McKesson Corp (NYSE:MCK) to resolve allegations the drug distributors contributed to the opioid epidemic in the state, Oklahoma Attorney General John O'Connor said on Monday.
O'Connor said Oklahoma recovered more money from the distributors than the state would have received if it had joined a nationwide $26 billion settlement that was announced last year.
The national settlement also includes Johnson & Johnson (NYSE:JNJ). Oklahoma sued J&J separately, but in November the case was thrown out on appeal, negating a $465 million trial judgment and undermining Oklahoma's legal theories in its opioid litigation.
AmerisourceBergen said drug distributors have been forced to "walk a legal and ethical tightrope" without clearer regulatory guidance on how to protect consumers from legal but potentially dangerous drugs.
"A settlement will avoid years of protracted litigation, expedite the movement of resources to communities impacted by opioid misuse and allow our company to do what we do best – ensuring that health care facilities like hospitals and community pharmacies have access to the medications that patients and care providers need," AmerisourceBergen spokeswoman Lauren Esposito said.
McKesson and Cardinal Health did not immediately respond to requests for comment.
Oklahoma was the last state pursuing litigation related to opioids against the three distributors. Alabama is still suing Cardinal Health and AmerisourceBergen after settling with McKesson. Local governments in West Virginia are pursuing cases after the state settled.
Oklahoma will use at least 85% of the funds to help abate the opioid addiction crisis in the state, according to O'Connor.
The distributors have denied wrongdoing in the epidemic, which has caused more than 500,000 U.S. overdose deaths during the past two decades, according to government data.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.